Background Cancer cachexia is known to adversely affect the clinical course in patients with
malignant lymphoma. The cachexia index (CXI) is a potential biomarker of cancer cachexia …

Aim: To assess treatment patterns, healthcare resource utilization (HCRU), and costs for
patients with diffuse large B-cell lymphoma (DLBCL) who did not receive stem cell …

Background Hypoalbuminemia is a common complication in patients with chronic kidney
disease (CKD) and is associated with various adverse clinical events. Currently, there are …

Introduction We characterized real-world treatment patterns in older (65–74 years) and
oldest (75–85 years) patients with diffuse large B-cell lymphoma (DLBCL) receiving initial …

PURPOSE Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-
CHOP) represents the standard of care for first-line treatment of diffuse large B-cell …

Context Treatment-related toxicities in DLBCL (diffuse large B cell lymphoma) patients are
higher in the initial phase of treatment (first cycle effect). Implementation of pre-phase …

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
lymphoma subtype worldwide and occurs frequently in the elderly population. However …

Purpose The treatment strategy for elderly patients older than 80 years with DLBCL has not
been defined yet because of poor treatment tolerability and lack of data. The aim of this trial …

临床上, 患者年龄≥ 90 岁的弥漫性大B 细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)
较为罕见, 目前尚缺乏标准治疗; 本文报道1 例病理诊断为弥漫性大B 细胞淋巴瘤患者, 年龄90 …

Background Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
lymphoma subtype worldwide and frequently occurs in the elderly population. However …